Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

9475	Companies
185442	Keywords
117783	Articles
99298	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

PRESS RELEASE

published on 11/22/2024 at 15:15, 1 year ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Dr. Reid Bissonnette, Executive Consultant for Translational Research and Development at Xenetic, presents positive preclinical data at SITC 39th Annual Meeting. Focus on advancing immune-oncology technologies to treat hard cancers

Cancer Treatment Preclinical Data Immunotherapy SITC 39th Annual Meeting Dr. Reid Bissonnette
BRIEF

published on 11/21/2024 at 14:35, 1 year ago

Xenetic Biosciences Reports Promising Preclinical Results for DNase I and CAR T Cell Therapy in Melanoma

Preclinical Study Melanoma DNase I CAR T Cells Oncology Therapy
BRIEF

published on 11/21/2024 at 14:35, 1 year ago

Xenetic Biosciences annonce des résultats précliniques prometteurs pour la thérapie par ADNase I et cellules CAR T dans le mélanome

Étude Préclinique Mélanome ADNase I Cellules CAR-T Thérapie Oncologique
PRESS RELEASE

published on 11/21/2024 at 14:30, 1 year ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Xenetic presents preclinical data on DNase I and CAR T cells' synergistic effects in treating solid tumors. Results show promise in modulating tumor microenvironment and enhancing therapeutic responses

Preclinical Data Solid Tumors Xenetic DNase I CAR T Cells
BRIEF

published on 11/13/2024 at 14:35, 1 year ago

Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2024

Résultats Financiers Développement Clinique Biosciences Xénétiques Plateforme D'oncologie DNase Partenariats Institutionnels
BRIEF

published on 11/13/2024 at 14:35, 1 year ago

Xenetic Biosciences Reports Q3 2024 Financial Results

Financial Results Xenetic Biosciences Clinical Development DNase Oncology Platform Institutional Partnerships
PRESS RELEASE

published on 11/13/2024 at 14:30, 1 year ago

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Xenetic Biosciences reports Q3 2024 financial results, progress in DNase-based platform for oncology, partnership with institutional collaborators, and $6.8 million cash balance

Xenetic Biosciences Oncology Q3 2024 Financial Results Institutional Partnerships DNase-based Platform
BRIEF

published on 11/12/2024 at 15:05, 1 year ago

Xenetic Biosciences annonce des résultats précliniques positifs pour la thérapie par DNase I et anti-CTLA-4 dans le cancer colorectal

Immunothérapie Biosciences Xénétiques Données Précliniques Thérapie À L'ADNase I Carcinome Colorectal
BRIEF

published on 11/12/2024 at 15:05, 1 year ago

Xenetic Biosciences Reports Positive Preclinical Results for DNase I and Anti-CTLA-4 Therapy in Colorectal Cancer

Xenetic Biosciences Preclinical Data Immunotherapy DNase I Therapy Colorectal Carcinoma
PRESS RELEASE

published on 11/12/2024 at 15:00, 1 year ago

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Positive preclinical data on systemic DNase I combined with CTLA-4 antibody presented at SITC 2024, targeting NETs to enhance antitumor immunity and generate immunological memory in MSS/MMRp CRC tumors

DNase I SITC 2024 CTLA-4 Antibody Antitumor Immunity Immunological Memory

Accesswire

Published on 12/05/2025 at 02:35, 9 hours 35 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 9 hours 40 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 11 hours 10 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 13 hours 5 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 13 hours 10 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 11:14, 55 minutes ago

Halfords Group PLC: Director/PDMR Shareholding
Published on 12/05/2025 at 11:08, 1 hour 1 minute ago

Linedata Services: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Published on 12/05/2025 at 10:30, 1 hour 40 minutes ago

Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 1 hour 54 minutes ago

Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 2 hours 29 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration

Les Echos

Published on 12/05/2025 at 08:45, 3 hours 25 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 3 hours 25 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 3 hours 27 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 17 hours 55 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 18 hours 10 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025

View all LES ECHOS COMFI WIRE